12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Nexavar sorafenib: Phase III data

The double-blind, international Phase III DECISION trial in 417 patients with locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer showed that twice-daily 400 mg oral Nexavar met the primary endpoint of improving PFS vs. placebo. The trial enrolled patients who had received no prior...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >